

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virginia 22313-1450 www.webje.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/790,730	03/03/2004	Makoto Ozeki	1422-0625P	2621
2592 7590 902280912 BIRCH STEWART KOLASCH & BIRCH PO BOX 747 FALLS CHURCH, VA 22040-0747			EXAMINER	
			CLAYTOR, DEIRDRE RENEE	
FALLS CHUR	.CH, VA 22040-0747		ART UNIT	PAPER NUMBER
		1627		
			NOTIFICATION DATE	DELIVERY MODE
			02/28/2012	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail $\,$ address(es):

mailroom@bskb.com

Advisory Action Before the Filing of an Appeal Brief

	Application No.	Applicant(s)	
	10/790,730	OZEKI ET AL.	
Examiner		Art Unit	
	Renee Claytor	1627	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 07 February 2012 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) The period for reply expires 6 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b), ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION, See MPEP 706,07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF ADDER

NOTICE OF APPEAL
 The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(a)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).
<u>AMENDMENTS</u>
 The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below);
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
(d) ☐ They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: . (See 37 CFR 1.116 and 41.33(a)).
4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s):
 Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling th non-allowable claim(s).
7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.
The status of the claim(s) is (or will be) as follows:
Claim(s) allowed:,
Claim(s) objected to:
Claim(s) rejected:
Claim(s) withdrawn from consideration:
AFFIDAVIT OR OTHER EVIDENCE
8. 🗌 The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered
because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and

was not earlier presented. See 37 CFR 1.116(e). 9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be

entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. A The request for reconsideration has been considered but does NOT place the application in condition for allowance because: see Continuation sheet.

 12. □ Note the 	e attached Informatio	n <i>Disclosure Stateme</i>	<i>ent</i> (s). (PTO/SB/08) Pa	per No(s)
13. Other:				

/Renee Claytor/ Primary Examiner, Art Unit 1627

Applicants present arguments over the 35 USC 103 rejection over Ueda et al. (US Patent 6,831,103) in view of Hamilton (J Neurol Neurosurg Psychiat, 1960, 23,56). In particular, it is argued that the cited references fall to disclose that at least the three symptoms recited in the claims can be treated. It is argued that when theanine is administered in the Ueda reference, one of ordinary skill in the art would not expect that only specific symptoms are improved when improvement in many symptoms of depression are not shown by the Hamilton scale. Applicants argue that to establish obviousness, all of the claim limitations must be disclosed by the cited references.

It is noted that Ueda et al. does not specifically use the words "feelings of guilt, suicide and retardation,pscyhomotor" when describing symptoms. However, Ueda et al. does teach symptoms that overlap with those listed in claim 5. Ueda et al. discusses the treatment of anxiogenic symptoms that can be associated with diminished homeostasis of which symptoms of diminished homeostasis include spiritesenses, agressiveness, faintheartendesses, maudiliness and psychological lift. Ueda et al. Leach symptoms that to verlap with the present claims, for example, anxiogenic symptoms are often indicated in feelings of guilt and suicide. Applicants arguments that Ueda fails to disclose that at least the three symptoms among the 21 symptoms of the Hamilton scale can be treated while showing effectiveness with statistical significance, this argument is now found persuasive. The claim is drawn to the treatment of symptoms of guilt, suicide, and retardation;pscyhomotor. There is no indication that these symptoms being treated are distinct from any of the other symptoms on the Hamilton scale. Accordingly, the rejection is deemed obvious.